Abstract
Early clinical development is often referred to as the “Valley of Death” in clinical trials because of the challenges involved in the translation from preclinical research to First in Human (FIH). The high attrition rate of drugs is widely attributable to the lack of data from the very basic and mechanistic assumptions made during the earliest phases of computational PK and screening, the limited preclinical studies executed in two species, and then the animal model factors used for allometric scaling.
Phase 1 is the first time that a novel compound is dosed to healthy normal volunteers, or in some specific cases, to patients with a targeted disease. The objective during this phase is to evaluate the risk to benefit to humans and to gain understanding of the administered doses and systemic drug concentrations, correlated to any observed adverse events via the route of administration intended for the product (IV, oral, subcutaneous, etc.). Increasingly, this phase is also concerned with pharmacodynamics, or physiological effects exerted by the novel drug over time.
This chapter is divided in two parts. The first part will elucidate the considerations which go into the design of early clinical research studies including drug disposition, pharmacokinetics, and pharmacodynamics and then clinical pharmacology clinical trial design, elements, and endpoints are examined in the second part.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References and Further Reading
Gad SC (ed) (2010) Pharmaceutical sciences encyclopedia: drug discovery, development, and manufacturing. Wiley, New York. Copyright ©
Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32(1):187–192. https://doi.org/10.2337/dc08-9026
Strimbu K, Tavel JA (2010) What are Biomarkers. Curr Opin HIV AIDS 5(6):463–466
United States of America. Center for Drug Evaluation and Research, Food and Drug Administration (2005) Guidance for industry: estimating the maximum safe starting dose in clinical trials for therapeutics in adult volunteers. Office of Training and Communications Division of Drug Information, Rockville
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Rusch, L.M., Dehn, C. (2020). Methods in Clinical Pharmacology. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-68864-0_28
Download citation
DOI: https://doi.org/10.1007/978-3-319-68864-0_28
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68863-3
Online ISBN: 978-3-319-68864-0
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences